IRIS Accounts Production v26.1.10.61 12196253 director 1.10.24 30.9.25 30.9.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh121962532024-09-30121962532025-09-30121962532024-10-012025-09-30121962532023-09-30121962532023-10-012024-09-30121962532024-09-3012196253ns15:EnglandWales2024-10-012025-09-3012196253ns14:PoundSterling2024-10-012025-09-3012196253ns10:Director12024-10-012025-09-3012196253ns10:PrivateLimitedCompanyLtd2024-10-012025-09-3012196253ns10:SmallEntities2024-10-012025-09-3012196253ns10:AuditExempt-NoAccountantsReport2024-10-012025-09-3012196253ns10:SmallCompaniesRegimeForDirectorsReport2024-10-012025-09-3012196253ns10:SmallCompaniesRegimeForAccounts2024-10-012025-09-3012196253ns10:AbridgedAccounts2024-10-012025-09-3012196253ns10:OrdinaryShareClass12024-10-012025-09-3012196253ns10:RegisteredOffice2024-10-012025-09-3012196253ns5:CurrentFinancialInstruments2025-09-3012196253ns5:CurrentFinancialInstruments2024-09-3012196253ns5:Non-currentFinancialInstruments2025-09-3012196253ns5:Non-currentFinancialInstruments2024-09-3012196253ns5:ShareCapital2025-09-3012196253ns5:ShareCapital2024-09-3012196253ns5:RetainedEarningsAccumulatedLosses2025-09-3012196253ns5:RetainedEarningsAccumulatedLosses2024-09-3012196253ns5:FurnitureFittings2024-10-012025-09-3012196253ns5:ComputerEquipment2024-10-012025-09-3012196253ns5:WithinOneYearns5:CurrentFinancialInstruments2025-09-3012196253ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3012196253ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2025-09-3012196253ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-09-3012196253ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-09-3012196253ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-09-3012196253ns10:OrdinaryShareClass12025-09-3012196253ns10:Director112024-09-3012196253ns10:Director112023-09-3012196253ns10:Director112024-10-012025-09-3012196253ns10:Director112023-10-012024-09-3012196253ns10:Director112025-09-3012196253ns10:Director112024-09-30
REGISTERED NUMBER: 12196253 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 September 2025

for

Callisto Life Science Partners Ltd

Callisto Life Science Partners Ltd (Registered number: 12196253)






Contents of the Financial Statements
for the Year Ended 30 September 2025




Page

Company Information 1

Abridged Statement of Financial Position 2

Notes to the Financial Statements 4


Callisto Life Science Partners Ltd

Company Information
for the Year Ended 30 September 2025







DIRECTOR: R Leach





REGISTERED OFFICE: 48a Malvern Road
Powick
Worcester
WR2 4RT





REGISTERED NUMBER: 12196253 (England and Wales)





ACCOUNTANTS: Davies Archytas Accountants Ltd
12-13 The Oaks
Clews Road
Redditch
Worcestershire
B98 7ST

Callisto Life Science Partners Ltd (Registered number: 12196253)

Abridged Statement of Financial Position
30 September 2025

30.9.25 30.9.24
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 3,249 790

CURRENT ASSETS
Debtors 41,046 96,853
Cash at bank 29,750 5,208
70,796 102,061
CREDITORS
Amounts falling due within one year 39,611 67,028
NET CURRENT ASSETS 31,185 35,033
TOTAL ASSETS LESS CURRENT
LIABILITIES

34,434

35,823

CREDITORS
Amounts falling due after more than one
year

26,954

30,970
NET ASSETS 7,480 4,853

CAPITAL AND RESERVES
Called up share capital 6 2 2
Retained earnings 7,478 4,851
SHAREHOLDERS' FUNDS 7,480 4,853

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Callisto Life Science Partners Ltd (Registered number: 12196253)

Abridged Statement of Financial Position - continued
30 September 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Income Statement and an abridged Statement of Financial Position for the year ended 30 September 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 May 2026 and were signed by:





R Leach - Director


Callisto Life Science Partners Ltd (Registered number: 12196253)

Notes to the Financial Statements
for the Year Ended 30 September 2025

1. STATUTORY INFORMATION

Callisto Life Science Partners Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

Callisto Life Science Partners Ltd (Registered number: 12196253)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2025

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 October 2024 9,338
Additions 4,305
At 30 September 2025 13,643
DEPRECIATION
At 1 October 2024 8,548
Charge for year 1,846
At 30 September 2025 10,394
NET BOOK VALUE
At 30 September 2025 3,249
At 30 September 2024 790

5. LOANS

An analysis of the maturity of loans is given below:

30.9.25 30.9.24
£    £   
Amounts falling due within one year or on demand:
Bank loans 5,705 5,705

Amounts falling due between one and two years:
Bank loans - 1-2 years 5,705 5,705

Amounts falling due between two and five years:
Bank loans - 2-5 years 21,249 25,265

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.9.25 30.9.24
value: £    £   
2 Ordinary £1 2 2

Callisto Life Science Partners Ltd (Registered number: 12196253)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2025

7. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 30 September 2025 and 30 September 2024:

30.9.25 30.9.24
£    £   
R Leach
Balance outstanding at start of year 62,849 63,385
Amounts advanced 86,293 59,287
Amounts repaid (141,176 ) (59,823 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 7,966 62,849

The overdrawn director's loan account is included within debtors. It is an interest free unsecured loan to the director, R Leach.

8. ULTIMATE CONTROLLING PARTY

During the financial year, the controlling party is the sole director, R Leach.